



Bacteriophage Lysins in the Era of Antibiotic Resistance

Guest Editor:

Prof. Dr. Hongping Wei
Wuhan Institute of Virology,
Chinese Academy of Sciences,
Wuhan, China

Deadline for manuscript
submissions:
closed (30 November 2021)

Message from the Guest Editor

Dear Colleagues,

The World Health Organization has listed microbial resistance to antibiotics among the major global health threats. It is not rare to see infections caused by bacteria resistant to all of the current antibiotics, leading to increased morbidity and mortality. This global challenge is provoking a high interest in seeking alternatives to traditional antibiotics. Bacteriophage lysins are hydrolytic enzymes capable of specifically recognizing the bacterial cell wall to cleave peptidoglycan for the release of progeny virions during the lytic cycle of bacteriophage. The advantages of lysins include fast bactericidal activity and low chance for bacteria to generate resistance. The aim of this Special Issue is to provide readers with an updated overview of the field, highlighting the most recent advances in lysin research.

We welcome contributions including, but not limited to, the following topics:

- Discovery and engineering variants of lysins;
- Synergistic combinations with other antimicrobials;
- Safety and host immune response;
- Development of lysins into pharmaceutical products;
- Other applications of lysins, such as in agriculture and cosmetics.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Nicholas Dixon

School of Chemistry and
Molecular Bioscience, University
of Wollongong, Wollongong, NSW
2522, Australia

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)

Contact Us

Antibiotics Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/antibiotics
antibiotics@mdpi.com
X@antibioticsmdpi